Merck Animal Health has launched an Equine Biosurveillance Pilot Program in Canada designed to help equine clinics with diagnosis of common equine respiratory diseases. The program will also collect epidemiological information on the main respiratory pathogens across Canada. This information can then be disseminated to the equine industry to promote knowledge of the ever-evolving nature of the pathogens.
Initially, Merck's Equine Biosurvelliance Program will be available to a limited number of clinics, but will eventually expand to include a significant number of practitioners. Clinics that are participating in the program will received a diagnostic kit that allows vets to collect and submit samples to the Diagnostic Service of the Faculté de Médecine Vétérinaire at the University of Montreal. There is no cost to the clinics to participate in this program.
The pathogens the program will test for include Equine Herpesvirus types 1 and 4, Equine Rhinitis A and B Viruses, Equine Influenza Virus, and Streptococcus equi subsp. equi. It is believed that this initiative will benefit the entire equine industry, including horse owners, barn managers, trainers and veterinarians, as best vaccination strategies are produced.
Read more at Equine Guelph.
New to the Paulick Report? Click here to sign up for our daily email newsletter to keep up on this and other stories happening in the Thoroughbred industry.
Copyright © 2020 Paulick Report.